Ocuphire Pharma Investor Updates

P 24 Next Steps Ocuphire Plans To Present Full Results At ASCRS In July And Move Into Phase 3 VEGA-1 Presbyopia Presentation by Dr. Pepose at ASCRS on Sunday July 25, 2021 at 8:45am ASCRS Paper ID 76645 SPS-204 Presbyopia Correcting IOL Comparisons, New Treatments and Studies MBCR - Level 2, Lagoon EF MIRA-2 Reversal of Mydriasis Presentation by Dr. Pepose at ASCRS on Monday July 26, 2021 at 4:25pm ASCRS Paper ID 76599 SPS-316 Corneal Diagnostic Studies MBCR-Level 2, Lagoon EF Advance into Phase 3 Presbyopia Registration Trials in 2022 Towards a Potential NDA in 2023 Ocuphire PHARMA

View entire presentation